Sign Up to like & get
recommendations!
0
Published in 2018 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2018.36.15_suppl.e15647
Abstract: e15647Background: Hypermutation, which is a molecular subtype with high tumor mutation burden (TMB), has been recognized as a biomarker of anti-PD-1 therapy in many cancers. Hypermutation can be de...
read more here.
Keywords:
detection hypermutation;
clinical morphological;
characterization detection;
hypermutation ... See more keywords